Gilead Sciences (GILD) Accounts Payables (2009 - 2026)

Gilead Sciences (GILD) has reported Accounts Payables for 18 consecutive years, with $645.0 million the latest figure, recorded in Q1 2026.

• Accounts Payables for Q1 2026 came in at $645.0 million, down 12.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $645.0 million (down 12.48% YoY), and the FY2025 annual result was $715.0 million, down 14.17% from the prior year.
• Accounts Payables was $645.0 million for Q1 2026 at Gilead Sciences, down from $715.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $905.0 million in Q4 2022 and troughed at $537.0 million in Q2 2024.
• Average Accounts Payables over 5 years is $672.6 million, with a median of $622.0 million recorded in 2023.
• Year-over-year, Accounts Payables sank 39.23% in 2023 and soared 54.1% in 2024.
• Over 5 years, Accounts Payables stood at $905.0 million in 2022, then tumbled by 39.23% to $550.0 million in 2023, then surged by 51.45% to $833.0 million in 2024, then declined by 14.17% to $715.0 million in 2025, then slipped by 9.79% to $645.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $645.0 million in Q1 2026, $715.0 million in Q4 2025, and $808.0 million in Q3 2025.